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ABSTRACT  14 
 15 
Aims: To construct a clinically plausible mathematical model of the patho-physiological dynamics of HIV-
1 induced AIDS during the acute and chronic phases which  incorporates the interactions between 
uninfected CD4+ T cells, HIV-1 infected CD4+ T cells, HIV-1 virions in the blood plasma, and specific 
cytotoxic CD8+ T cells. In particular, the model describes quantitatively the time evolution of AIDS in the 
patient during the acute phase and the asymptomatic chronic clinical latency phase and elucidates the 
effect of latent HIV-1 reservoirs on the prognosis of AIDS. The major objective is to derive mathematical 
criteria depicting the necessary and sufficient conditions under which the HIV-1 virions can be maintained 
definitely at the subclinical viral blood plasma level such that the HIV-1 seropositive person does not 
develop full-blown AIDS.. 
Study design: The model is based on contemporary published patho-physiological data on acute and 
clinical chronic phase HIV-1 induced AIDS. These data are meticulously condensed into a clinically 
plausible four compartmental mathematical model that incorporates the dynamics and interactions 
between non-HIV-1 infected CD4+ T lymphocytes. HiV-1 infected lymphocytes, free HIV-1 virions in the 
blood plasma, and HIV-1 specific cytotoxic CD8+ T lymphocytes. The relevant stoichiometric interaction 
rate constants, apoptotic  rate constants ,rate constats for viral recruitment from latent reservoirs, and 
other relevant parameters are clearly exhibited in the mathematical model.  
Place and Duration of Study: This research was done at Fayetteville State University, North Carolina 
USA, and is sponsored by the FSU Mini-Grant Award and the HBCU Graduate STEM Grant. The 
research was done during the Spring of 2012. 
Methodology:. The deterministic nonlinear HIV-1 AIDS patho-physio-dynamical equations are analyzed 
using the techniques of dynamical system theory, principles of linearized stability, Hartman-Grobman 
theory, and other relevant mathematical techniques. The clinically desirable equilibrium states are and 
their local existence and global stability are analyzed. Investigative computer simulations are performed 
illustrating some physiological outcomes. 
Results: Mathematical criteria are derived under which the clinically desired outcomes can occur.  
Investigative computer simulations are presented which elucidate a number of physiological scenarios of 
primary HIV-1 infection, involving the annihilation, and  persistence of HIV-1 in the absence of AIDS 
Pharmacotherapy 
Conclusion: Mathematical modeling can be a useful technique in the derivation of prognostic criteria and 
quantitative analysis of  AIDS  during the acute and chronic phases. 
. 
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1. INTRODUCTION  20 
Human Immunodeficiency Virus (HIV) belongs to a family of ribonucleic (RNA) lenti-viruses. In particular, the 21 
epidemiologically common subtype called HIV-1 is implicated for causing the Human Acquired Immunodeficiency 22 
Syndrome (AIDS). The pathogenesis of AIDS can be divided into three main phases called the acute phase, the 23 
clinical latency phase, and the full-blown AIDS phase.   24 
The HIV-1 virion uses the glycoprotein gp120 to locate the CD4 surface molecules and the host cells. By 25 
means of CCR5 or CXCR4, the HIV-1 virions fuses to the host cell surfaces and eventually enter the cell. The 26 
CD4+ T cells are the major targets for the HIV-1 virions. But macrophages, monocytes, neurons, astrocytes, and 27 
microglia cells in the central nervous system (CNS) possess CCR5 chemokine co-receptors and hence are 28 
targets of HIV-1 virions.  The pathogenesis of HIV-1 infection comprises the virus life cycle, the host cellular 29 
environment, and the viral load in the infected person. There exist strains of HIV-1 virus known as T-tropic and M-30 
tropic which interact respectively with the CXCR4 and CCR5 chemokine co-receptors .  31 
During the acute phase of HIV-1 infection, the person is seropositive after exposure and immunological 32 
reaction to the initial viral inoculum.  The person experiences transient infection resembling mononucleosis for 1-33 
12 weeks. The symptomatic primary HIV-1 infection is usually characterized by fever, lymphadenopathy, 34 
pharyngitis, arthralgia, rash, and lethargy. This is called acute retroviral syndrome (ARS) and is experienced by 35 
most but not all of the HIV-1 infected persons. During this phase, large amount of HIV-1 virions are produced 36 
inside the patient body. Inside the patient body, the HIV-1 viral envelope decoates and HIV RNA, reverse 37 
transcriptase, integrase, and other viral protein enter the host cell leading to formation of a pre-integration 38 
complex inside the host cell such as the CD4+ T cells. Then reverse transcriptase is used to produce HIV-1 viral 39 
DNA. The viral DNA is transported across the nucleus of the host cell and integrates into the host DNA. The next 40 
step is the production of new HIV-1 viral proteins using the HIV-1 viral RNA as genomic RNA. HIV proteases 41 
cleave newly synthesized polyproteins at the appropriate places to create the mature protein components of an 42 
infectious HIV virion. Then the new viral RNA and viral proteins migrate to the host surface and form a new 43 
immature HIV-1provirus. The mature newly formed HIV-1 virions exit the host cell by a process called budding. In 44 
particular, several millions of virus RNA copies may be released into the blood plasma of the patient.  45 
After 3 months, the chronic clinical latency phase starts. During this phase, the rate of HIV-1 replication in 46 
the host cell decreases as the CD4+ T cells numbers increases as a result of the cytotoxic intervention of the 47 
body’s immune system mounted by the CD8+ T cells. In particular, it is possible at this stage for the blood plasma 48 
HIV-1 viral titre to be subclinical and plunge to undetectable levels.  This may continue up to 8 years or longer. 49 
Pantaleo, G (1993); Siliciano, R. F. (1998); Wasef, N. M.(2003). 50 
The third phase of HIV-1 dynamics is characterized by a rapid exponential increase in the number of HIV-1 51 
virions in the blood plasma, increase in the number of HIV-1 infected CD4+ T cells, and a rapid decrease of 52 
uninfected CD4+ T cells to a level below 200 cells per microliter and a complete failure of the anti-HIV cytotoxic 53 
activity of CD8+ T cells. Walker, C. M. et al. (1986) 54 
Several mathematical models of HIV-1 dynamics have been constructed by many authors including Pantaleo 55 
et al (1993); Essunger, P., Perelson, A.S. (1994); Perelson, A.S., Nelson, P. (1999); Kirschner, D., Webb, G.F. 56 
(1996); Wodarz, D. et al. (1999); Wodarz, D. (2001); Wodarz, D., Nowark, M. (1999). These authors proposed 57 
various mathematical models which describe certain aspects of HIV-1 life cycle with the aim of finding criteria for 58 
cure of AIDS or present a quantitative analysis of the dynamics of the HIV-1 virus. Ciupe, M.S., Bivort, B.L., Bortz, 59 
D.M. and Nelson, P.W. (2006) presented a detailed analysis of three different mathematical models with regard to 60 
local and global stability of infected and uninfected equilibrium (steady) states of HIV-1 infection. Their analysis 61 
also included the dynamics of time delay models. Li, M.Y. and Shu, H. (2011) performed an elaborate analysis of 62 
the global dynamics of a mathematical model for HTLV-1 infection of CD4+ T cells with delayed CTL response. In 63 
particular, they demonstrated that the time delay can destabilize the system equilibrium leading to Hopf 64 
bifurcations and stable periodic oscillations. Similar analysis of the global dynamics of HIV-1 infection of CD4+ T 65 
cells was done by Wang, L. and Li, M.Y. (2006). They obtained some interesting results on the stability of infected 66 
and non-infected equilibrium states of AIDS infection. A stochastic model for HIV-1 population dynamics has been 67 
presented and analyzed by Tuckwell and Corfec (1998). In particular, they analyzed the random fluctuations 68 
associated with HIV-1 infection and dynamics. In the forthcoming paper, we will present a stochastic model of 69 
HIV-1 dynamics which incorporates viral contributions from latent reservoirs and also accounts for apoptosis. 70 
3 
 
In this paper, new mathematical models for the acute phase and the asymptomatic clinical latency phase are 71 
proposed and analyzed. In particular, elaborate and robust mathematical criteria will be presented elucidating the 72 
conditions under which the chronic clinical latency phase can be maintained indefinitely in the seropositive HIV-1 73 
infected person. 74 
 75 
2.DEFINITION AND DESCRIPTION OF MODEL PARAMETERS.  76 
 77 
The model of HIV-1 patho-physio- dynamics presented in this paper contains many variables and constant 78 
parameters. These parameters include stoichiometric interaction coefficients, cellular degradation rate constants, 79 
apoptotic rate constants, rate constants for production of immune cells from the thymus gland via haematopoietic 80 
progenitors, rate constants for recruitment of HIV-1 virions from latent reservoirs, intra-specific competition rate 81 
constants between infected / uninfected CD4+ T cells, and activation constants for CD4+/CD8+ T cells. The 82 
catalogue of constants is presented as follows 83 
x1: the number density of un-infected CD4
+ 
helper T-lymphocytes per unit volume 84 
x2: the number density of HIV-1 infected CD4
+ 
helper T-lymphocytes per unit volume 85 
x3: the number density of HIV-1 virions in the blood plasma per unit volume 86 
x4: the number density of HIV-1 specific CD8
+ 
cytotoxic T-lymphocytes per unit volume 87 
S1:  rate of supply of un-infected CD4
+
 T4-lymphocytes  88 
S2:  rate of supply of latency infected CD4
+
 T4-lymphocytes 89 
S3: rate of supply of HIV-1 virions from macrophage, monocytes, microglial cells and other lymphoid tissue 90 
different from T4-lymphocytes 91 
S4:  rate of supply of CD8
+ 
 T8-lymphocytes from the thymus 92 
ai, bi: constant associated with activation of lymphocytes by cytokine interleukin-2 (IL-2) 93 
αi: constant associated with HIV-1 infection of CD4
+
 T4 helper cells  94 
1: the number of HIV-1 virions produced per day by replication and budding in CD4
+
 T4 helper cells 95 
2: rate constant associated with replication and “budding” of HIV-1 in syncytia CD4
+
 T4 helper cells per day per 96 
micro liter (l) and released into the blood plasma 97 
3: the number of HIV-1 virions produced per day by replication and “budding” in non-syncytia CD4
+
 T4 helper 98 
cells and released into the blood plasma 99 
qi: constant depicting competition between infected and un-infected CD4
+
 T4 helper cells 100 
ki: constant depicting degradation, loss of clonogenicity or  “death” 101 
ei0: constant depicting death or degradation or removal by apoptosis (programmed cell death) 102 
Ki: constant associated with the killing rate of infected CD4
+
 T4 cells by CD8
+ 
 T8 cytotoxic lymphocytes 103 
 104 
.. 105 
3.  MODEL DESCRIPTION AND ANALYSIS 106 
In this section, the mathematical formulation for the acute and chronic phase of HIV-1 patho-physio-dynamics 107 
will be presented.  108 
3.1. The description of the mathematical model  109 
3.1.1 The CD4+ T cell dynamics:  110 
1011211311
2
1111
11 exkxxqxxexaSx
xb         (3.1) 111 
      112 
The instantaneous number of uninfected CD4+ T cells in the blood plasma of the patient at any time during 113 
the acute or chronic phase is equal to the rate of supply of uninfected CD4+ T cells from the thymus via 114 
hematopoietic progenitor cells (
1S ); plus the activation/proliferative recruitment of antigen activated and 115 
interleukin-2 stimulated CD4+ T cells ( 112
11
xb
exa
 ); less the number of CD4+ cells recruited into the pool of HIV-1 116 
infected CD4+ T cells by infection with HIV-1 virions (
311 xx ); less the number of CD4+ T cells lost by intra-117 
4 
 
specific competition with HIV-1 infected CD4+ T cells(
211 xxq ); less the number of CD4+ T cell lost by enzymatic 118 
degradation(
11xk ); and less the number of CD4+ T cells lost by apoptosis/exfoliative cytolytic death( 10e ). 119 
 120 
3.1.2 The HIV-1 infected CD4+ dynamics:  121 
20421312221231221222
12 exxKxxkxxqxxexxaSx
xb       (3.2) 122 
   123 
The instantaneous number of HIV-1 infected CD4+ T cells in the blood plasma of the patient during the acute 124 
or chronic phase is equal to the rate of supply of HIV infected CD4+ T cells from resting CD4+ T cells (
2S ); plus 125 
the activation/proliferative recruitment of antigen activated and interleukin-2 stimulated HIV-1 infected CD4+ T 126 
cells ( 12
212
xb
exxa
 );  plus the addition of the HIV-1 infected CD4+ T cells (
312 xx );less the number of CD4+ T 127 
cells lost by intra-specific competition with HIV-1 uninfected CD4+ T cells(
212 xxq ); less the number of HIV-1 128 
infected CD4+ T cell lost by enzymatic degradation(
22 xk ); and less the number of HIV-1 infected CD4+ T cells 129 
lost as a result of budding of newly produced virions (
31x ); less the number of HIV-1 infected CD4+ T cells lost 130 
by cytolytic action by HIV-1 specific CD8+ T cells(
421 xxK ); and less the number of HIV-1 infected CD4+ T cells 131 
lost by apoptosis/exfoliative cytolytic death(
20e ). 132 
3.1.3  The blood plasma HIV-1 virion dynamics:  133 
30333133332233 exkxxxxxSx         (3.3) 134 
      135 
The instantaneous number of HIV-1 virions in the blood plasma of the patient is equal to the rate of supply of 136 
HIV-1 virions from the latently infected viral reservoirs (
3S );  plus the number of HIV-1 virions released from the 137 
syncytia of CD4+ T cells/dendritic cells/macrophages (
322 xx ); plus the number of HIV-1 virions released from 138 
budding HIV-1 infected CD4+ T cells (
33x ); less the number of HIV-1 virions lost during infection of CD4+ T 139 
cells (
313 xx ); less the number of HIV-1 virions lost by enzymatic degradation/catabolism( 33xk ); and less the 140 
number of HIV-1 virions lost in the form of unintegrated HIV-1 DNA molecules per provirus ( 30e ).    141 
 142 
3.1.4  The CD8+ T cells dynamics:  143 
404442241444
14 exkxxKexxaSx
xb                                     (3.4) 144 
      145 
The instantaneous number of HIV-1 specific CD8+ T cells is equal to the rate of supply the thymus via 146 
hematopoietic progenitor cells; plus activation/proliferative recruitment of antigen activated and interleukin-2 147 
stimulated HIV-1 specific CD8+ T cells ( 14
414
xb
exxa
 );  less the number of CD8+ T cells lost during cytolysis of 148 
HIV-1 infected CD4+ T cells ();less the number of HIV-1 specific CD8+ T cell lost by enzymatic 149 
degradation(
44 xk ); less the number of HIV-1 specific CD8+ lost by apoptosis/exfoliative cytolytic death( 40e ). 150 
 151 
 152 
 153 
 154 
 155 
 156 
 157 
 158 
 159 
 160 
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3.2 The Cauchy problem for dynamics of HIV-1 during the acute and chronic phases 161 
 162 
In this section, the initial value problem (Cauchy problem) for HIV-1 dynamics during the acute and chronic 163 
phases will be mathematically analyzed and discussed with regard to well - posedness, dissipativity of solutions, 164 
and invariance of non-negativity. 165 
From the previous section, the mathematical model for HIV-1 dynamics during the acute and chronic phases 166 
can be described in terms of the following deterministic, non-linear, and coupled ordinary differential equations. It 167 
is assumed that within certain biological limits the environment of the interactions between the uninfected CD4+ T 168 
cells, HIV-1 infected CD4+ T cells, HIV-1 virions in the blood plasma, and HIV-1 specific CD8+ T cells is 169 
homogeneous, isotropic, and hence space independent. Thus ordinary differential equations can be used in the 170 
modeling. In the future, mathematical models using partial differential equations, stochastic differential equations, 171 
and delay differential equations will be presented. Thus that Cauchy problem is described by the following system 172 
of equations: 173 
 174 
 175 
                                  
 
176 
 177 
 
178 
 179 
 
 
180 
                                                                                                                                                (3.5) 
181 
 182 
 183 
Let t0 be the time of the initial HIV-1 infection; and define tL, tP, repectively, as the time at which the latency 184 
phase begins and the time at which the post latency phase of HIV-1 dynamics commences in a patient. In 185 
particular, the phases [t0, tL],  [tL, tP] depict respectively the acute phase and the chronic phase of primary HIV-1 186 
induced AIDS.  187 
 188 
 189 
3.3  Dissipativity and boundedness of solutions  190 
 191 
In this subsection, the dissipativity of the model equations will be discussed.    192 
 193 
Definition: Consider the autonomous system of ordinary differential equations: 194 
  195 
 196 
}...,,2,1,0|{
),(,
)()(
0
00
nixx
CFandxxwhere
xtxxFx
i
n
i
n
nnn
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




          
(3.6) 197 
                                                                                                                                     198 
 199 
 200 
Then the system (3.6) is dissipative if  201 
 202 
 203 
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t


)(lim  204 
 
205 
 
206 

















}4,3,2,1{)( 00
404442241444
30333133332233
20421312221231221222
1011211311
2
1111
14
12
11
iforxtx
exkxxKexxaSx
exkxxxxxSx
exxKxxkxxqxxexxaSx
exkxxqxxexaSx
ii
xb
xb
xb







6 
 
The invariance of non-negativity ,  ultimate boundedness of solutions and dissipativity of the model equations   
207 
will be shown as follows: 
208 
 
209 
 
210 
  Let 
 211 
 
212 
                                                                                                                                            (3.7) 
213 
Where tL is the time at which the latency phase begins. Similarly, tP is the time at which the post latency phase of 214 
HIV-1 dynamics commences in a patient and the time beyond which full-blown AIDS occurs. 215 
The system of differential equations (3.5) reduce to the following differential inequalities, for ],[ 0 pttt  : 216 
  







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4044444
3033333
2022222
1011111
exkCSx
exkCSx
exkCSx
exkCSx




                                                  (3.8)   
217 
                                                                                  
 
218 
Using the Kamke comparison technique (cf Nani, F., Freedman, H.I. (2000)), the differential inequalities lead 219 
to the following theorem. 220 
Theorem 3.1 221 
Let  
222 
  
223 
               
224 
                                                                            (3.9) 
225 
where  










4004
3003
2002
1001
)(
)(
)(
)(
xtx
xtx
xtx
xtx
 
226 
Consider the set 227 
 
 ii mxxxxxA   0),,,( 44321
 
228 
Then all solutions of the initial value problem (3.5) that originate in int+
4
 will eventually enter the set of A, such 229 
that the solution will be non-negative, ultimately bounded and remain in A for all t +. 230 
Proof   231 
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The differential inequalities (3.8) can be used to obtain the following expressions: 232 
            (3.10)   
233 
     
234 
where  }4,3,2,1{0 
 iandi
 
235 
Hence, for i = {1, 2, 3, 4}, 236 
i
iii
i
k
eCS
txSup 0)(lim

  237 
and 238 
          
239 
                                                                                (3.11)
 240 
 241 
Thus the flow associated with the system (3.5) is dissipative, and non-negatively invariant if Si +Ci – ei0 > 0. In 242 
particular, the flow associated with the model equations (3.5) will eventually enter the set A and remains trapped 243 
in A for
 
t 
+
, if xi0 int+
4
.  244 
3.4 Criteria for persistence of HIV-1 virions in the chronic phase  245 
In this section, the criteria for the persistence of HIV-1 virions during the chronic phase will be derived. 246 
The differential equation for the HIV-1 patho- physiodynamics during the clinical chronic phase is: 247 
30333133233 )( exkxxxStx    248 
 249 
where S3 is the reflux and repopulation rate of the plasma HIV-1 virions from the lymphoid tissue, microgial cells, 250 
reticules-endothelial cells, monocytes/macrophages and other sanctuaries. e30 is a constant degradation rate of 251 
HIV-1 virions. 2 is the “budding” rate constant of HIV-1 virions. 252 
 253 
Let 254 
            255 
                                                                                                  (3.12) 256 
 257 
and 258 
     0303  eS  259 
     30333133233
)( exkxLxStx          (3.13)                                                                                                  260 
By solving (3.13) using Kamke’s comparison technique [1, 12], the following inequality is obtained:     261 
      
tLk
ke
Lk
eS
tx
)(
2133
303
3
2133)(






      (3.14)                                                                                          
 262 
where k is a positive constant. 263 
In particular, the following theorems arise immediately: 264 
 265 
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Theorem 3.2. Suppose  266 
(i)    0303  eS  267 
(ii)   02133   Lk   
268 
Then 269 
     
0)(inflim
2133
303
3 



 Lk
eS
tx        (3.15)                                                                                         270 
 271 
where H is a bounded positive number of subclinical value.  As a consequence, the number of HIV-1 virions in the 272 
blood plasma of the AIDS patient during the chronic phase will exhibit persistence. The patient will not develop 273 
full-blown AIDS if the value of H is such that the patient does not experience immune system paralysis. 274 
 275 
Theorem 3.3. Suppose 276 
(i)    0303  eS   277 
(ii)   02133   Lk           (3.16) 278 
(iii)   





2133
3030
Lk
eS
  
279 
where ε is a small positive number.  
280 
Then the blood plasma HIV-1 viral titre is negligibly subclinical and the AIDS patient has insignificant HIV-1 
281 
RNA copies in the blood plasma during the chronic phase.  
282 
 283 
 284 
Theorem 3.4. Suppose 285 
(i) 02133   Lk                                             
 286 
(ii) 0303  eS            (3.17)
 287 
Then the number of HIV-1 virions in the blood plasma increases exponentially. The HIV-1 positive patient will 288 
develop full-blown AIDS. Consequently, the patient will ultimately loose immuno-competency and eventually die 289 
as a result of opportunistic infections.   290 
 
291 
 
292 
 
293 
4. ANALYSES  OF THE  PHYSIOLOGICAL OUTCOMES 294 
 295 
The clinically significant equilibrium patho-physiological outcomes of HIV-1 dynamics during the acute and 296 
chronic phases will be analyzed in this section using the principles of linearized stability. The outcomes are called 297 
equilibrium points or rest points of the model equations. The analyses will involve five clinically interesting 298 
equilibrium outcomes labeled {Ei: i =1, 2, 3, 4, 5}.  299 
4.1 Criteria for existence of physiological outcomes 300 
(i) E1 = [0, 0, 0, 0]: this represents the case in which uninfected CD4
+
 T cells, infected CD4
+
 T cells, HIV-1 virions 301 
in blood plasma, and HIV-1 specific CD8+ T cells are all destroyed. This leads to the immune system paralysis in 302 
which the patient dies of opportunistic bacteria or viral infection. This case is clinically feasible if Si - ei0 =0. 303 
(ii) E2 = [ 1xˆ , 0, 0, 4xˆ ]: this represents the case in which infected CD4
+
 T cells and HIV-1 virions in blood plasma 304 
are all destroyed. Clinical doctors working with HIV-1 infected patients would like to achieve this outcome. This 305 
equilibrium point is clinically possible under the following necessary conditions:  306 
 307 
  
 308 
                (4.1) 309 
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(iii) E3 = [0, 2x , 3x , 0]: this depicts a clinically worst case situation in which both uninfected CD4
+ 
T cells and HIV-311 
1 specific CD8
+
 T cells are destroyed. This equilibrium point is clinically possible under the following necessary 312 
conditions: 313 
 314 
 315 
                 (4.2) 316 
 317 
 318 
 319 
(iv) E4 = [ 1
~x , 0, 0, 0]: this is the most clinically desirable equilibrium point in which infected CD4+ T cells, plasma 320 
HIV-1 virions, and HIV-1 specific cytotoxic CD8+ T cells are all annihilated. The necessary conditions for the 321 
existence of this equilibrium point are: 322 
 323 
 324 
          (4.3) 325 
 326 
(v) E5 = [ 1x

, 2x

, 3x

, 4x

]: this case can only exist if the equation (3.0) exhibits persistence  in which all the four 327 
factors co-exist. The details of showing persistence in nonlinear systems of differential equations have been 328 
discussed by Nani, F., Freedman, H.I. (2000).  329 
There are other equilibrium points such as E[x1, x2, 0, 0], E[0, 0, x3, x4] and many planar or axial points. 330 
These are clinically uninteresting and are not considered in this paper, but will be analyzed in a future paper. 331 
 332 
4.2. Linearized stability analysis of physiological outcomes 333 
The Hartman-Grobman theorem can be used to investigate the local physiological stability of HIV-1 AIDS 334 
disease dynamics associated with the model equations, in the neighborhood of the physiological outcomes 335 
(equilibrium states). The mathematical model is nonlinear and as such it is difficult to obtain any meaningful 336 
quantitative criteria about the model. Fortunately, the Hartman-Grobman theorem guarantees that the information 337 
contained in the linearized system and the information contained the nonlinear system are equivalent in the 338 
neighborhood of the rest points.   339 
The Jacobian matrix of linearization near any physiological outcome is denoted symbolically by    340 
 341 
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355 
4.2.1     Criteria for annihilation of HIV-1 virions during the acute and chronic phases 
356 
The Jacobian matrix of linearization in the neighborhood of E2 is given by the following matrix: 
357 
                                                                                                         
358 
 
359 
(4.5)                                  
 360 
 361 
The application of the principle of linearized stability and local stability theorems lead to the following: 362 
 363 
 364 
 Theorem 4.1.  Suppose 365 
(i) 
1
ˆ
1111
11)ˆ2(ˆ kexbxa xb    < 0 366 
(ii) 
41212
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12
ˆˆˆ 12 xKkxqexa xb  < 0 367 
(iii) 
3133
ˆ kx                         (4.6)                                                                                              368 
(iv) 
4
ˆ
14
14ˆ kexa xb   < 0 369 
Then the rest point ]ˆ,0,0,ˆ[ 412 xxE is local attractor. In particular, the HIV-1 infected CD4+ T cells and the HIV-1 370 
virions in the blood plasma of the AIDS patient are temporarily annihilated during the acute and chronic phases in 371 
the absence of the pharmacotherapy.  372 
 373 
Theorem 4.2. Suppose the conditions of Theorem 4.1 hold, and the following additional conditions hold:   374 
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(iii) 4
ˆ
14
14ˆ kexa xb   378 
Then the local attractor E2 can be written in the following form: 379 
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The clinical implication of this result is that  the transient annihilation of the HIV-1 virions and HIV-1 infected 382 
CD4+ T cells occurs during the acute and chronic phases if CD4+ T cells and CD8+ T cells number densities are 383 
given respectively by  
1
2
b
 and 
11
2
1
22
2
Kb
ea b
b

. 384 
 385 
4.2.2 The criteria for transient immune system paralysis during the acute and chronic phases of AIDS 386 
 387 
One of the rest points corresponding the immune system paralysis during primary AIDS infection is E3. The 388 
Jacobian matrix of the linearization of the model equations in the neighborhood of E3 is given as follows: 389 
 390 
           (4.9) 
391 
  392 
 393 
 394 
The application of the principles of linearized stability gives the following result: 395 
 396 
Theorem 4.3. Let 397 
(i) 023322  kkx   398 
(ii) 0)( 33222321  kxkx          (4.10) 399 
                                                                                                       400 
Then the rest point E3 is local attractor. 401 
 402 
The clinical implication of Theorem 4.3 is that the immune system of the AIDS patient suffices transient 403 
paralysis when the conditions (4.10) hold. 404 
 405 
Theorem 4.4.  Suppose the conditions of Theorem 4.1 hold, and the following additional conditions hold:   406 
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(iv) 
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Then E2 is a local attractor.  412 
 413 
The analysis of other rest points will be done in a future publication.  414 
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4.3. Global stability analysis of physiological outcomes 423 
In this section, theoretical criteria will be presented for global stability of the clinically desirable physiological 424 
outcome ]ˆ,0,0,ˆ[ 412 xxE . 425 
 426 
Consider space        (4.12) 427 
 428 
The model equations (3.5) correspondingly reduce to the following: 429 
  430 
     431 
             (4.13) 432 
  433 
Consider the Liapunov functional [1, 12]: 434 
 435 
                                                                                                            436 
  437 
      (4.14) 438 
The derivative of V along the solution curves of the model equations yields the result: 439 
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Define the following Lebesgue measurable, functions which are of bounded variation: 442 
    
14
11
41441
2
111
),(
)(
xb
xb
exxaxxF
exaxG



                 (4.16)                                                                                              443 
)]ˆ)(ˆ(ˆ)]ˆ,ˆ(),()[ˆ(ˆ
)]ˆ)(ˆ(ˆ)]ˆ()()[ˆ(ˆ
)ˆˆˆ)(ˆ(ˆ
)ˆˆ)(ˆ(ˆ
)ˆ(ˆ)ˆ(ˆ
44444444141444
111111111111
4441444
ˆ
414444
11
2
1111
2
11111
44441111
*
1414
1111
xkxkxxcxxFxxFxxc
xkxkxxcxGxGxxc
xkexxaxkexxaxxc
xkexaxkexaxxc
xxxcxxxcV
xbxb
xbxb








                  (4.17)                                                                                                        
444 
         
2
44444141444
11111
2
1111
*
)ˆ(ˆ)]ˆ,ˆ(),()[ˆ(ˆ
)]ˆ()()[ˆ(ˆ)ˆ(ˆ
xxkcxxFxxFxxc
xGxGxxcxxkcV


               (4.18)                                                                                                           
445 
Let 
 446 
          447 
             (4.19)                                                                                                          448 
and 449 
 450 
                                                                                                                   451 
 452 
 453 
 454 
 455 
and define define A={aij}M2X2(R) such that 456 
),0(ˆ}4,1{
)ˆ(ˆ
2
1
: 2




Rcandiwhere
xxcV
i
iii










}4,1{)( 00
404441444
1011
2
1111
14
11
iforxtx
exkexxaSx
exkexaSx
ii
xb
xb


442
111
ˆ
ˆ
xxv
xxv


2
2
1






 R
v
v
X
13 
 
(4.20) 457 
                   458 
 459 
 460 
 461 
then 462 
              (4.21)                                                                                                     463 
 464 
Where X
T
 denotes the transpose of X and 
*
V  is negative definite if the eigen-values of A have negative real parts.  465 
 In particular, the [aij]2x2 are defined as follows: 466 
 467 
 468 
                (4.22)                                                                                                469 
 470 
 471 
 472 
As the flow dynamics approaches the steady state E2[x1, 0, 0, x4], the following conditions hold: 473 
 474 
 475 
 476 
              (4.23)                                                                                           477 
 478 
but 479 
              480 
                                                                                                                             (4.24) 481 
 482 
Hence, the sufficient criteria for the global asymptotic stability of E2  are specified in the following 483 
theorem.  484 
 485 
Theorem 4.5. Suppose the following conditions hold: 486 
(i) Criterion (4.1) 487 
(ii)
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Then the clinically desirable rest point E2 is a global attractor. 490 
 491 
The clinical implication of Theorem 4.5 is that the AIDS patient will experience permanent annihilation of the 492 
infected CD4+ T cells and HIV-1 virions in the blood plasma if the patient’s patho-physio-dynamics conforms to 493 
the conditions specified in the theorem.    494 
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 499 
5. COMPUTER SIMULATION RESULTS AND DISCUSSION 500 
In this section, investigative computer simulations are performed under specific parametric configurations. It 501 
must be stated emphatically that Theorems 4.1 – 4.4 are applicable only to the equilibrium configurations {Ei: i =1, 502 
2, 3, 4, …, n}. of the patho-physiodynamics of HIV-1 virus in the AIDS patient. These theorems are “if…then…” 503 
theorems and as such are fulfilled only when the AIDS dynamics attains the equilibrium configuration in the 504 
patient. In particular, there exist certain sufficient but not necessary criteria under which the AIDS patient can 505 
experience clinically favorable outcomes. On the other hand, under the specified conditions of Theorems 4.1-4.4 506 
the predicted results are valid. The simulation results are presented in Sections 5.1 through 5.4. The time profile 507 
for the simulation is measured in years. 508 
The problem of parameter estimation in mathematical modeling of physiological systems is a non-trivial one. 509 
There is a quasi-uniqueness of patho-physio-dynamics of disease in the patient and as such no two persons have 510 
identical physiological parametric configurations for a given disease. These phenomena have been discussed in 511 
the publication by Wu, H. et al. (1999). Several techniques concerning parameter estimation have been discussed 512 
by many authors including Ciupe, M.S. et al. (2006), Perelson, A.S., et al. (1996); Perelson, A.S., and Nelson, P. 513 
(1999); Han, C. et al. (2002); Graziosi, C. et al. (1993);  Chun, T.W., et al. (1996); Wodarz, D., et al. (1999); 514 
Wodarz, D., and Nowark, M. (1999).  515 
Theorems 4.1-4.4, however, are based on equilibrium configurations of patho-physio-dynamics of AIDS. 516 
Thus, the techniques presented in the above references must be modified in order to obtain relevant estimates of 517 
the dynamical variables presented in this paper. In particular, in vitro and in vivo experiments as well as human 518 
biopsies from the peripheral blood of the AIDS patient are required in order to accurately determine most of the 519 
dynamical variables and constants of the model.  Simulations based on equilibrium dynamics of AIDS using ACSL 520 
(Advanced Continuous Simulation Language) will be presented in a forthcoming paper.   521 
5.1 Simulation results for hypothetical AIDS patient #1  522 
The hypothetical patient #1 possesses a non-equilibrium patho-physio-dynamics parametric configuration P1 523 
presented in Table 1. The HIV-1 dynamics in this patient represents the classic profile for the acute and clinically 524 
chronic phases of AIDS. The simulation results for patient #1 are exhibited in Figure 1. It can observed that the 525 
HIV-1 infected CD4+ T cells and the blood plasmas HIV-1 virions are completely eradicated in this patient without 526 
the use of anti-AIDS pharmaco-therapeutic drug protocols.  In addition, patient #1 experiences immune system 527 
reconstitution as the uninfected CD4+ T cells repopulate and proliferate towards their pre-HIV-1 infection carrying 528 
capacities.   529 
Table 1 Parametric Configuration 1 530 
 531 
S1 = 1.5 /day/l 
a1 = 0.009 /day/cell/l 
b1 = 0.001 /cell/l 
α1 = 0.05/day/virion/l 
k1 = 0.005/day/l 
q1 = 0.0045/day/l/cell 
e10 = 8.8 cells/day/l 
x10 = 703 cells/l 
S2 = 0.85 /day/l 
a2 = 0.004 /day/cell/l 
b2 = 0.004/cell/l 
α2= 0.1/day/virion/l 
k2 = 0.05/day/l 
q2 = 0.0001/day/l/cell 
1 = 50 virons/CD4
+
/day 
K1 = 0.001/day/l 
e20 = 0.005 cells/day/l 
x20 = 100 cells/l 
 
S3 = 0.0 /day/l 
2 = 0 virons/CD4
+
/day/l 
3 = 50 virons/CD4
+
/day 
α3 = 0.0027/day/virion/l 
k3 = 0.0001/day 
e30 = 0.0001 /day 
x30 = 0.01 cells/l 
S4 = 0.272 /day/l 
a4 = 0.0075 /day/cell/l 
b4 = 0.001/cell/l 
K2 = 0.0024 /day/l 
k4 = 0.001/day/l 
e40 = 7.75 cells/day/l 
x40 = 800 cells/l 
15 
 
 532 
 533 
 534 
   535 
   536 
Figure 1 Simulation results using parametric configuration 1 537 
 538 
5.2 Simulation results for hypothetical AIDS patient #2  539 
For this simulation, the hypothetical AIDS patient #2 is assigned the patho-physiological parameter 540 
configuration presented in Table 2. As in the previous simulation, the configuration P2 does not depict an 541 
equilibrium configuration. The simulation results are exhibited in Figure 2. It can be observed that the patient does 542 
not have a clinically favorable prognosis. Because the disease has apparently progressed beyond the time point 543 
characterized as tp , which is defined as the threshold time for full-blown AIDS.  As presented in Figure 2, the 544 
patient undergoes immune system paralysis in which the CD4+ T cells transiently destroyed. On the other hand, 545 
the cytotoxic activity of CD8+ T cells appears to be potent as observed in the eradication of the HIV-1 infected 546 
CD4+ T cells. Paradoxically the plasma HIV-1 viremia increases exponentially in the patient resulting in a more 547 
morbid AIDS outcome.  548 
Table 2 Parametric Configuration 2 549 
S1 = 1.5 /day/l 
a1 = 0.009 /day/cell/l 
b1 = 0.001 /cell/l 
α1 = 0.05/day/virion/l 
k1 = 0.005/day/l 
q1 = 0.0045/day/l/cell 
e10 = 8.8 cells/day/l 
x10 = 703 cells/l 
S2 = 0.85 /day/l 
a2 = 0.004 /day/cell/l 
b2 = 0.004/cell/l 
α2= 0.1/day/virion/l 
k2 = 0.05/day/l 
q2 = 0.0001/day/l/cell 
1 = 51 virons/CD4
+
/day 
K1 = 0.001/day/l 
e20 = 0.005 cells/day/l 
x20 = 200 cells/l 
S3 = 10.5 /day/l 
2 = 0.025    
       virons/CD4
+
/day/l 
3 = 51 virons/CD4
+
/day 
α3 = 0.027/day/virion/l 
k3 = 0.0001/day 
e30 = 0.0001 /day 
x30 = 5.5 cells/l 
S4 = 0.272 /day/l 
a4 = 0.0075 /day/cell/l 
b4 = 0.001/cell/l 
K2 = 0.0024 /day/l 
k4 = 0.08/day/l 
e40 = 10.75 cells/day/l 
x40 = 800 cells/l 
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 554 
Figure 2 Simulation results using parametric configuration 2 555 
5.3 Simulation results for hypothetical AIDS patient #3  556 
The patho-physiological parametric configuration of patient #3 is shown in Table 3. It must be noted that the 557 
AIDS in this patient is in the acute phase and as such the simulation results span a time period lasting up to one 558 
year. The results of the simulation are in Figure 3. This is a non-equilibrium AIDS configuration simulation as it is 559 
evident by the simulation time profile. The simulation results show that at the end of the acute phase, the AIDS 560 
patient experiences annihilation of uninfected CD4+ T cells. In addition, the HIV-1 specific CD8+ T cells eradicate 561 
successfully the HIV-1 infected CD4+ T cells. Unfortunately the immune system paralysis, which occurs as a 562 
consequence of the low CD4+ T cell number density, eventually leads to an exponential increase of the blood 563 
plasma HIV-1 viremia. This simulation represents an unfavorable AIDS outcome during the acute phase.       564 
Table 3 Parametric Configuration 3 565 
S1 = 1.5 /day/l 
a1 = 0.009 /day/cell/l 
b1 = 0.001 /cell/l 
α1 = 0.05/day/virion/l 
k1 = 0.005/day/l 
q1 = 0.0045/day/l/cell 
e10 = 8.8 cells/day/l 
x10 = 703 cells/l 
S2 = 0.0 /day/l 
a2 = 0.004 /day/cell/l 
b2 = 0.004/cell/l 
α2= 0.1/day/virion/l 
k2 = 0.05/day/l 
q2 = 0.0001/day/l/cell 
1 = 10 virons/CD4
+
/day 
K1 = 0.001/day/l 
e20 = 0.005 cells/day/l 
x20 = 100 cells/l 
 
S3 = 0.0 /day/l 
2 = 0.0 virons/CD4
+
/day/l 
3 = 10 virons/CD4
+
/day 
α3 = 0 /day/virion/l 
k3 = 0.0001/day 
e30 = 0.0001 /day 
x30 = 0.01 cells/l 
S4 = 0.272 /day/l 
a4 = 0.0075 /day/cell/l 
b4 = 0.001/cell/l 
K2 = 0.0024 /day/l 
k4 = 0.001/day/l 
e40 = 7.75 cells/day/l 
x40 = 800 cells/l 
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Figure 3 Simulation results using parametric configuration 3 572 
5.4 Simulation results for hypothetical AIDS patient #4 573 
The simulation results for hypothetical patient #4 are exhibited in Figure 4. These simulation results are 574 
based on the patho-physiological parametric configuration P4. In this patient the AIDS disease progresses from 575 
the acute phase into a 6 year clinically chronic phase before the development of full-blown AIDS.   576 
Table 4 Parametric Configuration 4 577 
S1 = 1.5 /day/l 
a1 = 0..5 /day/cell/l 
b1 = 0.001 /cell/l 
α1 = 0.05/day/virion/l 
k1 = 0.005/day/l 
q1 = 0.0045/day/l/cell 
e10 = 8.8 cells/day/l 
x10 = 703 cells/l 
S2 = 0.0 /day/l 
a2 = 0.05 /day/cell/l 
b2 = 0.004/cell/l 
α2= 0.5/day/virion/l 
k2 = 0.05/day/l 
q2 = 0.0001/day/l/cell 
1 = 2 virons/CD4
+
/day 
K1 = 0.001/day/l 
e20 = 0.005 cells/day/l 
x20 = 100 cells/l 
 
S3 = 0.0 /day/l 
2 = 0.0001    
       virons/CD4
+
/day/l 
3 = 2 virons/CD4
+
/day 
α3 = 0.0001/day/virion/l 
k3 = 0.0001/day 
e30 = 0.0001 /day 
x30 = 0.01 cells/l 
S4 = 0.272 /day/l 
a4 = 0.0075 /day/cell/l 
b4 = 0.001/cell/l 
K2 = 0.0024 /day/l 
k4 = 0.08/day/l 
e40 = 7.75 cells/day/l 
x40 = 800 cells/l 
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Figure 4 Simulation results using parametric configuration 4 583 
5.5 Simulation results for hypothetical AIDS patient #5 584 
This scenario represents a relatively favorable progression of AIDS in hypothetical patient #5. The data for 585 
the simulation results are given in Table 5 and the simulation results are displayed in Figure 5. The patho-586 
physiological parametric configuration of this patient does not represent an equilibrium configuration and as such 587 
the condition of theorems 4.1-4.4 are not applicable.  It can be observed from the simulation results that the 588 
patient would develop full-blown AIDS approximately after 10 years. On the other hand, the patient experiences 589 
relatively good immune-competency from the beginning of the initial infection up to approximately 10 years before 590 
the onset of full-blown AIDS.  591 
Table 5 Parametric Configuration 5 592 
S1 = 1.5 /day/l 
a1 = 2.5 /day/cell/l 
b1 = 0.001 /cell/l 
α1 = 0.05/day/virion/l 
k1 = 0.005/day/l 
q1 = 0.0045/day/l/cell 
e10 = 8.8 cells/day/l 
x10 = 703 cells/l 
S2 = 0.0 /day/l 
a2 = 0.05 /day/cell/l 
b2 = 0.004/cell/l 
α2= 0.5/day/virion/l 
k2 = 0.05/day/l 
q2 = 0.0001/day/l/cell 
1 = 2 virons/CD4
+
/day 
K1 = 0.001/day/l 
e20 = 0.005 cells/day/l 
x20 = 100 cells/l 
 
S3 = 0.0 /day/l 
2 = 0.0001    
       virons/CD4
+
/day/l 
3 = 2 virons/CD4
+
/day 
α3 = 0.0001/day/virion/l 
k3 = 0.0001/day 
e30 = 0.0001 /day 
x30 = 0.01 cells/l 
S4 = 0.272 /day/l 
a4 = 4.0 /day/cell/l 
b4 = 0.001/cell/l 
K2 = 0.0024 /day/l 
k4 = 0.001/day/l 
e40 = 7.75 cells/day/l 
x40 = 800 cells/l 
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Figure 5 Simulation results using parametric configuration 5 598 
5.6 Simulation results for hypothetical AIDS patient #6 599 
The patho-physiological configuration of hypothetical patient #6 is given in Table 6. The simulation results 600 
depict an AIDS scenario which progresses from the acute phase through a relatively short chronic phase and 601 
heading towards the development of full-blown AIDS, as shown in Figure 6. It can be observed also that from the 602 
time period between 0 to 4 years the patient has sufficient immuno-competency as it is evident in the relatively 603 
higher dynamic number density of the CD4+ T cells and the HIV-1 specific CD8+ T cells as compared to the low 604 
dynamic number density of the HIV-1 infected CD4+ T cells and the blood plasma HIV-1 virions. Beyond the 605 
period of 6 years, then blood plasma HIV-1 virion and the HIV-1 infected CD4+ T cells number densities begin to 606 
rise as the patient heads towards the development of full-blown AIDS.  607 
Table 6 Parametric Configuration 6 608 
S1 = 1.5 /day/l 
a1 = 1.5 /day/cell/l 
b1 = 0.001 /cell/l 
α1 = 0.05/day/virion/l 
k1 = 0.005/day/l 
q1 = 0.0045/day/l/cell 
e10 = 8.8 cells/day/l 
x10 = 703 cells/l 
S2 = 0.0 /day/l 
a2 = 0.05 /day/cell/l 
b2 = 0.004/cell/l 
α2= 0.5/day/virion/l 
k2 = 0.05/day/l 
q2 = 0.0001/day/l/cell 
1 = 2 virons/CD4
+
/day 
K1 = 0.001/day/l 
e20 = 0.005 cells/day/l 
x20 = 100 cells/l 
 
S3 = 0.0 /day/l 
2 = 0.0001    
       virons/CD4
+
/day/l 
3 = 2 virons/CD4
+
/day 
α3 = 0.0001/day/virion/l 
k3 = 0.0001/day 
e30 = 0.0001 /day 
x30 = 0.01 cells/l 
S4 = 0.272 /day/l 
a4 = 3.0 /day/cell/l 
b4 = 0.001/cell/l 
K2 = 0.0024 /day/l 
k4 = 0.001/day/l 
e40 = 7.75 cells/day/l 
x40 = 800 cells/l 
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Figure 6 Simulation results using parametric configuration 6 614 
 615 
 616 
6. SUMMARIZING REMARKS 617 
 618 
In this paper, we have presented a novel and robust approach to the study of HIV-1 dynamics during the 619 
acute and chronic phases. The special contribution of this model includes an explicit role of source terms S1, S2, 620 
S3, S4, which depict recruitment from the thymus gland and the HIV-1 viral reservoirs. Clinically relevant activation 621 
functions describing the action of IL-2 on the T cells are also included in the model equations. The clinical 622 
outcomes are clearly exhibited together with the associated criteria for existence. In particular, the simulation 623 
results depict the scenario of chronic asymptomatic HIV-1 infection during chronic latency phase in which the 624 
infected CD4
+
 T cells and the plasma, viremia are annihilated. The results elucidate and exhibit additional details 625 
of HIV-1 dynamics than the cited literature. In a future publication, investigative computer simulation results will be 626 
presented elucidating Theorems 4.1-4.4. In particular, the simulation software ACSL (Advanced Continuous 627 
Simulation Language) will be used in the simulation of time delay versions of model equations (3.5).  628 
 629 
7. REFERENCES 630 
 631 
[1] Amann, H., (1990). Ordinary Differential Equations, An Introduction to Nonlinear Analysis, Walter de Gruyter 632 
& Co, Berlin., pp. 209 633 
[2] Chun, T., Engel, D., Berrey, M., Shea, T., Corey, L., and Fauci, A., (1998). Early establishment of a pool of 634 
latently infected, resting CD4+ T cells during primary HIV-1 infection, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 635 
8869–8873. 636 
[3] Chun, T.W., Finzi D, Margolick, J. (1996). Fate of HIV-1 infected T-cells in vivo: Rates of transition to stable 637 
latency. Nat Med 1996; 334:1222-1330. 638 
21 
 
[4] Ciupe, M.S., Bivort, B.L., Bortz, D.M.,, and Nelson, P.W., (2006). Estimating kinetic parameters from HIV 639 
primary infection data through the eyes of three different mathematical models, Mathematical Biosciences 640 
200 pp. 1–27 641 
[5] Clark, S.J., Shaw, G.M. (1993). The acute retroviral syndrome and the patho-genesis of HIV-1 infection, 642 
Semin Immunology; 5:149 643 
[6] Daar, E.S. (1991). Transient high levels of viremia in patients with primary human immunodeficiency virus 644 
type I infection. New Engl. J. Med; 324:961 645 
[7] Essunger, P., Perelson, A. S. (1994). Modeling HIV infection of CD 4+ T-cell subpopulations. J. thero. Biol.  646 
170(4):367-91 647 
[8] Graziosi, C. (1993).  Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during 648 
primary HIV-1 infection. Proc Natl Acad Sci. USA, 90:6405  649 
[9] Han, C., Chaloner, K., Perelson, A.S., (2002). Bayesian analysis of a population HIV dynamic model. Case 650 
Studies in Bayesian Statistics, Vol.6, Springer-Verlag: New York, 651 
[10] Kirschner, D., Webb, G.F.(1996). A model for treatment strategy in the chemotherapy of AIDS. Bull. Math. 652 
Biol. 58, 367-390. 653 
[11] Li, M.Y.,  Shu, H.(2011). Global dynamics of a mathematical model for HTLV-1 infection of CD4+ T cells with 654 
delayed CTL response, Nonlinear Analysis: Real World Applications  doi:10.1016/j.nonrwa.2011.02.026    655 
[12] Nani, F. Freedman, H.I.(2000). A mathematical model of cancer treatment by immunotherapy. Mathematical 656 
Biosciences 163  159-199.  657 
[13] Nowark, M.A, Bangham, C.R.M. (1996). Population dynamics of immune responses to persistent viruses. 658 
Science 272, 74-79, 1996. 659 
[14] Pantaleo, G., Graziosi. C., Demarest, J.F. (1993). HIV infection is active and progressing in lymphoid tissue 660 
during the clinically latent stage of disease. Nature, 362:355-358. 661 
[15] Perelson, A.S., Neumann, A.U., Markwitz, M. (1996). Viral dynamics in vivo: virion clearance rate, infected 662 
cell life-span, viral generation time. Science, 271:1582-1586. 663 
[16] Perelson, A.S., Nelson, P. (1999) Mathematical analysis of HIV-1 dynamics in vivo, SIAM Rev. 41(1), 3-44. 664 
[17] Reddy, Y.S., Kashuba, A. (2003). Importance of antiretroviral drug concentration in sanctuary sites and viral 665 
reservoirs. AIDS Research and Human Retroviruses, Vol. 19 (11), pp. 167-176.   666 
[18] Rubbert, A. (2002). Course of HIV RNA in CD4+ and CD8+ lymphocytes in HIV-infected patients undergoing 667 
HAART as determined by ultrasensitive fluorescence in Situ hybridization (UFISH). Proc. of the 9
th
 Conf. on 668 
Retroviruses and Opportunistic Infections. 669 
[19] Siliciano, R.F. (1998). Immunodeficiency in HIV-1 infection in: AIDS and Other Manifestations of HIV 670 
Infection, 3
rd
 ed. Wormser,G. (Ed.) pp.257-278, Lippincott-Raven Publishers, Philadelphia. 671 
[20] Sonza, S., Crowe, S. (2001). Reservoirs for HIV infection and their persistence in the face of undetectable 672 
viral load. AIDS Patient Care and STDs; 15(10). 673 
[21] Suspène, R., Meyerhans, A. (2012). Quantification of Unintegrated HIV-1 DNA at the Single Cell Level In 674 
Vivo. PLoS ONE 7(5): e36246. doi:10.1371/journal.pone.0036246. 675 
[22] Tuckwell, H.C., Corfec, E.L., (1998). A stochastic model for early HIV-1 population dynamics.  J. theor. Biol. 676 
195, 451-463. 677 
[23] Walker, C.M., Moody, D.J., Stites, D.P., Levy, J.A. (1986). CD8
+
 lymphocytes can control HIV infection in vitro 678 
by suppressing virus replication. Science, 234:1563-1566. 679 
[24] Wang, L, Li MY, Mathematical analysis of the global dynamics of a model for HIV infection of CD4+ T cells. 680 
Math Biosci 200:44–57, 2006 681 
[25] Wassef, N. M., Young, J. Miller, R. (2003). Viral reservoirs/transient infection in HIV/AIDS: where are we now 682 
and where should we go? AIDS Research and Human Retroviruses, Vol. 19 (11), pp. 333-344. 683 
[26] Wodarz, D., Lloyd, A. (1999). Dynamics of macrophage and T cell infection by HIV. J. theor. Biol. 196, 101-684 
113. 685 
[27] Wodarz, D. (2001). Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for 686 
drug therapy and resistance. J.theor. Biol. 213, 447-459. 687 
22 
 
[28] Wodarz, D., Nowark, M. (1999). Specific therapy regimes could lead to long-term immunological control of 688 
HIV. Pro. Natl. Acad. Sci. USA 96(25), 14464-14469. 689 
[29] Wu, H., Ding, A., DeGruttola, V. (1999). Why are the decay rates in plasma HIV-1 different for different 690 
treatments and in different patient populations? AIDS, 13(3): 429-430. 691 
